Zhang Mengting, Dai Wei, Si Yuexiu, Shi Yetan, Li Xiangyuan, Jiang Ke, Shen Jingyi, Ying Liying
The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Front Oncol. 2022 Jan 24;11:762921. doi: 10.3389/fonc.2021.762921. eCollection 2021.
Although minimally invasive surgery (MIS) was commonly used to treat patients with early-stage cervical cancer, its efficacy remained controversial.
We systematically searched PubMed, Web of Science, and Cochrane Library databases until March 2021 to compare the prognosis of early-stage cervical cancer patients who underwent MIS (laparoscopic or robot-assisted radical hysterectomy) or ARH. The primary outcomes included rates of 3- and 5-year disease-free survival (DFS) and overall survival (OS). The study protocol was registered in PROSPERO: CRD42021258116.
This meta-analysis included 48 studies involving 23346 patients (11220, MIS group; 12126, ARH group). The MIS group had a poorer medium-term (3-year) DFS (HR=1.08, 95% CI: 1.01-1.16, =0.031) than the ARH group, without significant difference in medium-term OS as well as long-term (5-year) DFS and OS. Subgroup analysis of 3-year prognosis revealed that although patients in Western countries who underwent MIS had shorter DFS than those who underwent ARH (HR=1.10, =0.024), no difference was observed in DFS among those in Asian countries. Moreover, MIS was linked to poorer 3-year DFS in patients with stage I cervical cancer (HR=1.07, =0.020). Notably, subgroup analysis of 5-year prognosis revealed that patients with tumor size ≥2 cm undergoing MIS exhibited a shorter DFS than those who underwent ARH (HR=1.65, =0.041).
Patients with early-stage cervical cancer undergoing MIS may have a poorer prognosis than those undergoing ARH. Therefore, applying MIS in early-stage cervical cancer patients should be conducted with caution.
The study protocol was registered in PROSPERO: CRD42021258116.
尽管微创手术(MIS)常用于治疗早期宫颈癌患者,但其疗效仍存在争议。
我们系统检索了截至2021年3月的PubMed、科学网和考克兰图书馆数据库,以比较接受MIS(腹腔镜或机器人辅助根治性子宫切除术)或ARH的早期宫颈癌患者的预后。主要结局包括3年和5年无病生存率(DFS)及总生存率(OS)。该研究方案已在国际前瞻性系统评价注册库(PROSPERO)注册:CRD42021258116。
这项荟萃分析纳入了48项研究,涉及23346例患者(11220例,MIS组;12126例,ARH组)。MIS组的中期(3年)DFS较ARH组差(HR = 1.08,95%CI:1.01 - 1.16,P = 0.031),中期OS以及长期(5年)DFS和OS无显著差异。3年预后的亚组分析显示,尽管西方国家接受MIS的患者DFS短于接受ARH的患者(HR = 1.10,P = 0.024),但亚洲国家患者的DFS无差异。此外,I期宫颈癌患者中,MIS与较差的3年DFS相关(HR = 1.07,P = 0.020)。值得注意的是,5年预后的亚组分析显示,肿瘤大小≥2 cm的接受MIS的患者DFS短于接受ARH的患者(HR = 1.65,P = 0.041)。
接受MIS的早期宫颈癌患者的预后可能比接受ARH的患者差。因此,在早期宫颈癌患者中应用MIS应谨慎。
该研究方案已在国际前瞻性系统评价注册库(PROSPERO)注册:CRD42021258116。